here are two gems:
1) I labeled that call as confusing.
2) Go check just saw pant-genius' PT of 46. he loves quantum jump theory i guess
its very obvious by your tone that you lost your #$%$ on advaxis and now you want to spread your misery to the adro board.
Roth Capital affirms Aduro Biotech (Nasdaq: ADRO) with a Buy/Focus Pick rating and $46 price target after ADRO announced that the first patient has been dosed in SEASCAPE, the Phase 1/2 clinical study designed to evaluate the safety, tolerability and preliminary efficacy of CRS-207, Aduro’s lead listeria-based immunotherapy construct (LADD), in combination with epacadostat (INCB24360), Incyte Corporation’s selective IDO1 inhibitor, in patients with ovarian cancer.
Analyst Joseph Pantginis commented: We continue to be impressed with the expanding profile of CRS-207. A combination with an IDO inhibitor makes inherent sense to us based on removing the pressure of T-regulatory cells on the immune system. Our thesis for Aduro and CRS-207 remains strong. The lead value driver currently for the stock is the Phase IIb ECLIPSE study in pancreatic cancer, expected to read out in late 2Q16.
To this end, we believe the boxes are checked supporting a positive outcome of the study: 1) a well-designed and run, randomized Phase IIa clinical study, which showed statistically significant improvements in survival for both the primary endpoint and multiple subgroups, 2) Phase IIa published in the peer reviewed Journal of Clinical Oncology and 3) long-term survivors continue to be treated and monitored (i.e. characteristic immunotherapy "tail").